209 related articles for article (PubMed ID: 33549538)
1. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
Harrison RF; Fu S; Sun CC; Zhao H; Lu KH; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2021 Jul; 225(1):68.e1-68.e11. PubMed ID: 33549538
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
Zhong L; Tran AT; Tomasino T; Nugent E; Smith JA
J Manag Care Spec Pharm; 2018 Dec; 24(12):1219-1228. PubMed ID: 30479195
[TBL] [Abstract][Full Text] [Related]
3. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Cheng H; Yang J; Liu H; Xiang Y
Arch Gynecol Obstet; 2021 Aug; 304(2):285-296. PubMed ID: 34021367
[TBL] [Abstract][Full Text] [Related]
4. Out-of-Pocket Spending for Non-Birth-Related Hospitalizations of Privately Insured US Children, 2017 to 2019.
Carlton EF; Becker NV; Moniz MH; Scott JW; Prescott HC; Chua KP
JAMA Pediatr; 2023 May; 177(5):516-525. PubMed ID: 36972040
[TBL] [Abstract][Full Text] [Related]
5. Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting.
Chase DM; Annavarapu S; Tseng WY; Shi J; Szamreta E; Monberg M
Gynecol Oncol; 2024 Jan; 180():79-85. PubMed ID: 38056115
[TBL] [Abstract][Full Text] [Related]
6. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
McGarvey N; Gitlin M; Fadli E; Chung KC
J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
[TBL] [Abstract][Full Text] [Related]
7. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10.
Drew Y; Kristeleit RS; Oaknin A; Ray-Coquard I; Haris NM; Swisher EM
Oncologist; 2020 Jan; 25(1):e109-e119. PubMed ID: 31575788
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting.
Rimel BJ; Chase DM; Perhanidis J; Ghazarian AA; Du EX; Wang T; Song J; Golembesky AK; Hurteau JA; Kalilani L; Salani R; Monk BJ
Gynecol Oncol Rep; 2024 Feb; 51():101332. PubMed ID: 38362364
[TBL] [Abstract][Full Text] [Related]
9. A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
Gao W; Muston D; Monberg M; McLaurin K; Hettle R; Szamreta E; Swallow E; Zhang S; Kalemaj I; Signorovitch J; McQueen RB
Pharmacoeconomics; 2020 Nov; 38(11):1201-1218. PubMed ID: 32794041
[TBL] [Abstract][Full Text] [Related]
10. Cost sharing for oral lenvatinib among commercially insured patients.
Liang MI; Chen L; Aviki EM; Wright JD
Am J Manag Care; 2024 Mar; 30(3):114-117. PubMed ID: 38457819
[TBL] [Abstract][Full Text] [Related]
11. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
Spargo A; Yost C; Squires P; Raju A; Schroader B; Brown JD
J Manag Care Spec Pharm; 2021 May; 27(5):554-564. PubMed ID: 33908275
[No Abstract] [Full Text] [Related]
12. Prescription Drug Dispensing and Patient Costs After Implementation of a No Behavioral Health Cost-Sharing Law.
Golberstein E; Campbell JM; Maclean JC; Harris SJ; Saloner B; Stein BD
JAMA Health Forum; 2024 Mar; 5(3):e240198. PubMed ID: 38517423
[TBL] [Abstract][Full Text] [Related]
13. How Have Patient Out-of-pocket Costs for Common Outpatient Orthopaedic Foot and Ankle Surgical Procedures Changed Over Time? A Retrospective Study From 2010 to 2020.
Goldfarb SI; Xu AL; Gupta A; Mun F; Durand WM; Gonzalez TA; Aiyer AA
Clin Orthop Relat Res; 2024 Feb; 482(2):313-322. PubMed ID: 37498201
[TBL] [Abstract][Full Text] [Related]
14. The Out-of-Pocket Cost Burden of Cancer Care-A Systematic Literature Review.
Iragorri N; de Oliveira C; Fitzgerald N; Essue B
Curr Oncol; 2021 Mar; 28(2):1216-1248. PubMed ID: 33804288
[TBL] [Abstract][Full Text] [Related]
15. Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices.
Bartoletti M; Cecere SC; Musacchio L; Sorio R; Puglisi F; Pignata S
ESMO Open; 2021 Jun; 6(3):100135. PubMed ID: 33930658
[No Abstract] [Full Text] [Related]
16. Drug use and spending under a formulary informed by cost-effectiveness.
Yeung K; Cruz M; Tsiao E; Watkins JB; Sullivan SD
J Manag Care Spec Pharm; 2023 Nov; 29(11):1175-1183. PubMed ID: 37889867
[No Abstract] [Full Text] [Related]
17. High Deductibles are Associated With Severe Disease, Catastrophic Out-of-Pocket Payments for Emergency Surgical Conditions.
Scott JW; Neiman PU; Scott KW; Ibrahim AM; Fan Z; Fendrick AM; Dimick JB
Ann Surg; 2023 Oct; 278(4):e667-e674. PubMed ID: 36762565
[TBL] [Abstract][Full Text] [Related]
18. Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors.
Gupta S; Hanna PE; Ouyang T; Yamada KS; Sawtell R; Wang Q; Katz-Agranov N; Feghali L; Krasner CN; Bouberhan S; Castro CM; Sise ME
J Natl Cancer Inst; 2023 Jul; 115(7):831-837. PubMed ID: 37074956
[TBL] [Abstract][Full Text] [Related]
19. Designing a Value-Based Formulary for a Commercial Health Plan: A Simulated Case Study of Diabetes Medications.
Chen Y; Loucks AR; Sullivan SD; Pearson SD; Kent D; Yeung K
Value Health; 2023 Jul; 26(7):1022-1031. PubMed ID: 36796479
[TBL] [Abstract][Full Text] [Related]
20. Is there a "low-risk" patient population in advanced epithelial ovarian cancer?: a critical analysis.
Chambers LM; O'Malley DM; Coleman RL; Herzog TJ
Am J Obstet Gynecol; 2022 Nov; 227(5):728-734. PubMed ID: 35640700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
